Trial Profile

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Psilocybin (Primary)
Indications Bipolar II disorders
Focus Therapeutic Use

Most Recent Events

06 Dec 2023 Results published in the COMPASS Pathways Media Release.
06 Dec 2023 According to a Sheppard Pratt Health System Media Release, this trial is initiated and led by Scott T. Aaronson and funded by Compass Pathways.
06 Dec 2023 According to a Sheppard Pratt Health System Media Release, data from this trial were published in the JAMA Psychiatry.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com